Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2842089 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Protein Kinase, CGMP-Dependent, Type II (PRKG2) (AA 714-744), (C-Term) antibody
- Antibody type
- Polyclonal
- Description
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 714-744, C-Term
- Antibody clone number
- RB01036
- Vial size
- 80 μL
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Submitted references Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines.
Nitric oxide/cyclic guanosine monophosphate inducers sodium nitroprusside and L-arginine inhibit the proliferation of gastric cancer cells via the activation of type II cyclic guanosine monophosphate-dependent protein kinase.
Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction.
Autophosphorylation of cGMP-dependent protein kinase type II.
Inhibition of cGMP-dependent protein kinase II by its own splice isoform.
Molecular cloning, cDNA structure, and chromosomal localization of the human type II cGMP-dependent protein kinase.
Expression of the human cGMP-dependent protein kinase II gene is lost upon introduction of SV40 T antigen or immortalization in human cells.
Jiang LU, Wu M, Wu Y, Lan T, Wang Y, Qian H, Chen Y
Oncology letters 2015 Jun;9(6):2781-2786
Oncology letters 2015 Jun;9(6):2781-2786
Nitric oxide/cyclic guanosine monophosphate inducers sodium nitroprusside and L-arginine inhibit the proliferation of gastric cancer cells via the activation of type II cyclic guanosine monophosphate-dependent protein kinase.
Yao X, Wu Y, Zhu M, Qian H, Chen Y
Oncology letters 2015 Jul;10(1):479-484
Oncology letters 2015 Jul;10(1):479-484
Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction.
Rangaswami H, Marathe N, Zhuang S, Chen Y, Yeh JC, Frangos JA, Boss GR, Pilz RB
The Journal of biological chemistry 2009 May 29;284(22):14796-808
The Journal of biological chemistry 2009 May 29;284(22):14796-808
Autophosphorylation of cGMP-dependent protein kinase type II.
Vaandrager AB, Hogema BM, Edixhoven M, van den Burg CM, Bot AG, Klatt P, Ruth P, Hofmann F, Van Damme J, Vandekerckhove J, de Jonge HR
The Journal of biological chemistry 2003 Aug 1;278(31):28651-8
The Journal of biological chemistry 2003 Aug 1;278(31):28651-8
Inhibition of cGMP-dependent protein kinase II by its own splice isoform.
Gambaryan S, Palmetshofer A, Glazova M, Smolenski A, Kristjansson GI, Zimmer M, Lohmann SM
Biochemical and biophysical research communications 2002 May 24;293(5):1438-44
Biochemical and biophysical research communications 2002 May 24;293(5):1438-44
Molecular cloning, cDNA structure, and chromosomal localization of the human type II cGMP-dependent protein kinase.
Orstavik S, Solberg R, Taskén K, Nordahl M, Altherr MR, Hansson V, Jahnsen T, Sandberg M
Biochemical and biophysical research communications 1996 Mar 27;220(3):759-65
Biochemical and biophysical research communications 1996 Mar 27;220(3):759-65
Expression of the human cGMP-dependent protein kinase II gene is lost upon introduction of SV40 T antigen or immortalization in human cells.
Fujii M, Ogata T, Takahashi E, Yamada K, Nakabayashi K, Oishi M, Ayusawa D
FEBS letters 1995 Nov 20;375(3):263-7
FEBS letters 1995 Nov 20;375(3):263-7
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC